tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2014 Aug 2. doi: 10.1111/irv.12272. [Epub ahead of print]
A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.
Schmeisser F1, Vasudevan A, Soto J, Kumar A, Williams O, Weir JP.
Author information
Abstract
BACKGROUND:
The potency of inactivated influenza vaccines is determined using a single radial immunodiffusion (SRID) assay. This assay is relatively easy to standardize, it is not technically demanding, and it is capable of measuring the potency of several vaccine strain subtypes in a multivalent vaccine. Nevertheless, alternative methods that retain the major advantages of the SRID, but with a greater dynamic range of measurement and with reduced reagent requirements, are needed.
OBJECTIVES:
The feasibility of an ELISA-based assay format was explored as an alternative potency assay for inactivated influenza vaccines.
METHODS:
Several murine monoclonal antibodies (mAbs), specific for the 2009 pandemic H1N1 influenza virus hemagglutinin (HA), were evaluated for their potential to capture and quantify HA antigen. Vaccine samples, obtained from four licensed influenza vaccine manufacturers, included monovalent bulk vaccine, monovalent vaccine, and trivalent vaccine. Traditional SRID potency assays were run in parallel with the mAb-ELISA potency assay using the reference antigen standard appropriate for the vaccine samples being tested.
RESULTS:
The results indicated that the ELISA potency assay can quantify HA over a wide range of concentrations, including vaccine at subpotent doses, and the ELISA and SRID potency values correlated well for most vaccine samples. Importantly, the assay was capable of quantifying A/California HA in a trivalent formulation.
CONCLUSIONS:
This study demonstrates the general feasibility of the mAb approach and strongly suggests that such ELISAs have potential for continued development as an alternative method to assay the potency of inactivated influenza vaccines.
? 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
KEYWORDS:
Influenza virus vaccine; monoclonal antibody; potency assay
PMID:
25087462
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25087462
A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.
Schmeisser F1, Vasudevan A, Soto J, Kumar A, Williams O, Weir JP.
Author information
Abstract
BACKGROUND:
The potency of inactivated influenza vaccines is determined using a single radial immunodiffusion (SRID) assay. This assay is relatively easy to standardize, it is not technically demanding, and it is capable of measuring the potency of several vaccine strain subtypes in a multivalent vaccine. Nevertheless, alternative methods that retain the major advantages of the SRID, but with a greater dynamic range of measurement and with reduced reagent requirements, are needed.
OBJECTIVES:
The feasibility of an ELISA-based assay format was explored as an alternative potency assay for inactivated influenza vaccines.
METHODS:
Several murine monoclonal antibodies (mAbs), specific for the 2009 pandemic H1N1 influenza virus hemagglutinin (HA), were evaluated for their potential to capture and quantify HA antigen. Vaccine samples, obtained from four licensed influenza vaccine manufacturers, included monovalent bulk vaccine, monovalent vaccine, and trivalent vaccine. Traditional SRID potency assays were run in parallel with the mAb-ELISA potency assay using the reference antigen standard appropriate for the vaccine samples being tested.
RESULTS:
The results indicated that the ELISA potency assay can quantify HA over a wide range of concentrations, including vaccine at subpotent doses, and the ELISA and SRID potency values correlated well for most vaccine samples. Importantly, the assay was capable of quantifying A/California HA in a trivalent formulation.
CONCLUSIONS:
This study demonstrates the general feasibility of the mAb approach and strongly suggests that such ELISAs have potential for continued development as an alternative method to assay the potency of inactivated influenza vaccines.
? 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
KEYWORDS:
Influenza virus vaccine; monoclonal antibody; potency assay
PMID:
25087462
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25087462